Antifungal resistance in pathogenic fungi.
Pathogenic fungi are the cause of life-threatening infections in an increasing number of immunocompromised patients. The intrinsic resistance to antifungal therapy observed in some genera, along with the development of resistance during treatment in others, is becoming a major problem in the management of these diseases. We reviewed the epidemiology of the most common systemic fungal infections for which antifungal resistance is a potential problem, the mechanisms of antifungal resistance, the correlation between in vitro susceptibility testing and clinical outcome, and the clinical implications of antifungal resistance.
Perea
Sofia
S
Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Patterson
Thomas F
TF
D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000453:epidemiology; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology; D025141:Drug Resistance, Fungal / Q000502:physiology*; D005437:Flucytosine / Q000494:pharmacology / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D016867:Immunocompromised Host; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D016896:Treatment Outcome
D000935:Antifungal Agents; D000666:Amphotericin B; D005437:Flucytosine